Empaa-M (12.5/500mg) 14 Tablets

It contain empagliflozin, an orally-active inhibitor of the sodium-glucose co-transporter 2 (SGLT2). Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus as: Monotherapy when diet and exercise alone do not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate due to intolerance. In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycemic control.

Metformin, Empagliflozin

Tablet

Diabetes Type 2

Dose must be taken according to the doctor’s advice only; doses given below are suggested as supportive literature for better understanding in some areas of requirements. Adult dose: The recommended starting dose is 10mg of empagliflozin once daily the dose can be increased to 25mg once daily. The maximum daily dose is 25mg. When (empagliflozin) is used in combination with a sulphonylurea or with Insulin, a lower dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia.

Overdose may lead to hypoglycemia, consult your doctor immediately in case of overdose. Multiple daily doses of up to 100mg empagliflozin (equivalent to 4 times the highest recommended daily dose) in patients with type 2 diabetes did not show any toxicity.

In case you missed any dose, take the next dose as soon as you remember, but don't double your next dose to compensate for the missed one.

Take it orally as advised by the doctor.

(Empagliflozin) is contraindicated in: Patients with known hypersensitivity to empagliflozin or to any excipient of the product, Severe renal impairment, end-stage renal disease or dialysis.

Hypoglycemia(when used with sulfonylurea or insulin) Vaginal moniliasis Vulvovaginitis Balanitis and other genital infection Urinary tract infection. Pruritus (generalized) and increased urination Uncommon; Volume depletion Dysuria and blood creatinine increased / glomerular filtration rate decreased. Rare; Diabetic ketoacidosis.

(Empagliflozin) causes intravascular volume contraction. Symptomatic hypotension may occur after initiating empagliflozin particularly in patients with renal impairment. Empagliozin increases serum creatinine and decreases eGFR. The risk of impaired renal function with empagliflozin is increased in elderly patients and patients with moderate renal impairment.

Store at 25°C. Protect from heat and moisture.